mRNA Lipid Nanoparticles for Ex Vivo Engineering of Immunosuppressive T Cells for Autoimmunity Therapies

Nano Lett. 2023 Nov 22;23(22):10179-10188. doi: 10.1021/acs.nanolett.3c02573. Epub 2023 Oct 31.

Abstract

Cell-based therapies for autoimmune diseases have gained significant traction, with several approaches centered around the regulatory T (Treg) cell─a well-known immunosuppressive cell characterized by its expression of the transcription factor Foxp3. Unfortunately, due to low numbers of Treg cells available in circulation, harvesting and culturing Treg cells remains a challenge. It has been reported that engineering Foxp3 expression in CD4+ T cells can result in a Treg-like phenotype; however, current methods result in the inefficient engineering of these cells. Here, we develop an ionizable lipid nanoparticle (LNP) platform to effectively deliver Foxp3 mRNA to CD4+ T cells. We successfully engineer CD4+ T cells into Foxp3-T (FP3T) cells that transiently exhibit an immunosuppressive phenotype and functionally suppress the proliferation of effector T cells. These results demonstrate the promise of an LNP platform for engineering immunosuppressive T cells with potential applications in autoimmunity therapies.

Keywords: Foxp3; T cell engineering; autoimmune diseases; lipid nanoparticles; mRNA delivery.

MeSH terms

  • Autoimmune Diseases* / genetics
  • Autoimmune Diseases* / therapy
  • Autoimmunity
  • Forkhead Transcription Factors / genetics
  • Forkhead Transcription Factors / metabolism
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • T-Lymphocytes, Regulatory* / metabolism

Substances

  • Lipid Nanoparticles
  • Immunosuppressive Agents
  • Forkhead Transcription Factors